GRI - GRI Bio, Inc.
GRI Bio, Inc. , a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis.
- Sector
- Healthcare
- Industry
- Biotechnology
- Market Cap
- $188,647
- Beta
- -1.22
- 52-Week Range
- 1.97-80.36
- CEO
- W. Marc Hertz
- Employees
- 3
- IPO Date
- Apr 24, 2023
- Exchange
- NASDAQ
GRI Options Snapshot
Options pricing data for GRI is refreshed daily after the close. When listed contracts exist, this page surfaces the latest at-the-money implied volatility, max pain strike, dealer gamma exposure (GEX), and 25-delta skew. Listed contracts and live snapshots appear once the options chain has been published by the exchange for the most recent session.
What This Page Covers
The GRI overview links into per-metric analysis views: max pain, gamma exposure, volatility skew, expected move, options chain, open interest history, and aggregate Greeks. Microstructure data is available on short interest, short volume, fail-to-deliver, and market structure. Corporate data is on fundamentals, earnings, analyst ratings, and insider trading.
Frequently asked GRI overview questions
- What is GRI?
- GRI is the ticker symbol for GRI Bio, Inc., a listed security. GRI Bio, Inc. , a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Listed on NASDAQ. GRI is the equity ticker shown on this page; equity options traders use the security for directional, volatility, and income strategies via the listed options chain.
- What are GRI's key statistics?
- GRI Bio, Inc. (GRI) carries a market capitalization of $188,647, beta of -1.22 relative to the broader market, 52-week range of 1.97-80.36. Full income statement, balance sheet, cash flow, and TTM ratio history is on the per-ticker fundamentals page; daily price history and 52-week levels are accessible from the same view. These structural inputs frame how the options market prices implied volatility around earnings windows and capital events.
- What sector or industry does GRI belong to?
- GRI Bio, Inc. operates in the Healthcare sector, in the Biotechnology industry. Sector classification affects how the ticker correlates with sector ETFs, how it reacts to macro factors like rate moves and commodity prices, and how its options pricing compares to sector peers. Compare GRI's implied volatility and skew against sector benchmarks to gauge whether the options market is pricing single-name or systemic risk relative to the broader peer group.
- How current is the GRI data on this page?
- Options snapshots refresh after each trading session; if no snapshot is currently posted for GRI, it usually reflects low options liquidity or a recently listed name. Company-profile fields (sector, industry, market cap, P/E, IPO date) refresh from the vendor feed nightly. Financials and earnings refresh as 10-K and 10-Q filings are parsed (typically within several business days of the actual report). FINRA microstructure data refreshes on the source's cadence (daily for short volume, bi-monthly for short interest, weekly for the OTC volume file, twice-monthly for SEC FTD).